Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A MULTICENTER, OPEN-LABEL, SINGLE-ARM SAFETY STUDY OF HERCEPTIN SC IN COMBINATION WITH PERJETA AND DOCETAXEL IN TREATMENT OF PATIENTS WITH HER2−POSITIVE ADVANCED BREAST CANCER (METASTATIC OR LOCALLY RECURRENT)

Next Previous
X
Search
Trial Profile

A MULTICENTER, OPEN-LABEL, SINGLE-ARM SAFETY STUDY OF HERCEPTIN SC IN COMBINATION WITH PERJETA AND DOCETAXEL IN TREATMENT OF PATIENTS WITH HER2−POSITIVE ADVANCED BREAST CANCER (METASTATIC OR LOCALLY RECURRENT)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Docetaxel
  • Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer
  • Focus Adverse reactions; Registrational
  • Acronyms MetaPHER
  • Sponsors Roche

    • Most Recent Events

    • 01 Jun 2021 Results of primary and final analysis (n=412) assessing safety, tolerability and efficacy of first-line subcutaneous trastuzumab plus intravenous fixed-dose pertuzumab and docetaxel intravenous in patients with HER2-positive metastatic breast cancer, published in the Breast Cancer Research and Treatment.
    • 14 Dec 2019 Results (data cutoff: 23 May 2019) of final analysis evaluating safety and tolerability were presented at the 42nd Annual San Antonio Breast Cancer Symposium
    • 18 Nov 2019 According to an Roche media release, data from this study will be presented at the San Antonio Breast Cancer Symposium (SABCS).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top